Relmada Q4 net loss $37.9M; cash at $148.3M; plans revised REL-1017 MDD trials after Study 301 failure

RELMADA THERAPEUTICS, INC.

Q4 2022 net loss $37.9M ($1.28/diluted share), vs $34.4M ($1.80) in Q4 2021; full-year net loss $157.0M.
Cash and short-term investments $148.3M at Dec 31, 2022, down from $211.9M a year earlier.
Will amend ongoing Phase 3 Study 302 and initiate new Study 304 for REL-1017 as adjunctive MDD treatment.
Appointed Cedric O'Gorman, M.D. as CMO and Fabiana Fedeli as independent board director.
Study 302 enrollment expected H1 2024; Study 304 to start mid-2023 with data in H2 2024.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

RELMADA THERAPEUTICS, INC. reported for the year ended December 31, 2022 results: net income -$157.0 million, EPS -$5.30.

Period: for the year ended December 31, 2022
Net income: -$157.0 million
EPS: -$5.30
Result: preliminary results

Exact text from the filing

Net loss for the year ended December 31, 2022 and 2021 was $157.0 million and $125.8 million, respectively. The Company had a net loss of $5.30 and $7.16 per share for the year ended December 31, 2022 and 2021, respectively.

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

RELMADA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001213900-23-022428

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.